TY - JOUR
T1 - Risk Factors for Mortality in Adult COVID-19 Patients Who Develop Bloodstream Infections Mostly Caused by Antimicrobial-Resistant Organisms: Analysis at a Large Teaching Hospital in Italy
AU - Posteraro, Brunella
AU - De Angelis, Giulia
AU - Menchinelli, Giulia
AU - D'Inzeo, Tiziana
AU - Fiori, Barbara
AU - De Maio, Flavio
AU - Cortazzo, Venere
AU - Sanguinetti, Maurizio
AU - Spanu Pennestri, Teresa
PY - 2021
Y1 - 2021
N2 - The aim of this study was to characterize COVID-19 (SARS-CoV-2-infected) patients who
develop bloodstream infection (BSI) and to assess risk factors associated with in-hospital mortality.
We conducted a retrospective observational study of adult patients admitted for 48 h to a large
Central Italy hospital for COVID-19 (1 March to 31 May 2020) who had or had not survived at
discharge. We included only patients having blood cultures drawn or other inclusion criteria satisfied.
Kaplan–Meier survival or Cox regression analyses were performed of 293 COVID-19 patients studied,
46 patients (15.7%) had a hospital-acquired clinically relevant BSI secondary to SARS-CoV-2 infection,
accounting for 58 episodes (49 monomicrobial and 9 polymicrobial) in total. Twelve episodes (20.7%)
occurred at day 3 of hospital admission. Sixty-nine species were isolated, including Staphylococcus
aureus (32.8%), Enterobacterales (20.7%), Enterococcus faecalis (17.2%), Candida (13.8%) and Pseudomonas
aeruginosa (10.3%). Of 69 isolates, 27 (39.1%) were multidrug-resistant organisms. Twelve (54.5%) of 22 patients for whom empirical antimicrobial therapy was inappropriate were infected by a multidrug-resistant organism. Of 46 patients, 26 (56.5%) survived and 20 (43.5%) died. Exploring variables for association with in-hospital mortality identified > 75-year age (HR 2.97, 95% CI 1.15–7.68,p = 0.02), septic shock (HR 6.55, 95% CI 2.36–18.23, p < 0.001) and BSI onset 3 days (HR 4.68, 95% CI 1.40–15.63, p = 0.01) as risk factors independently associated with death. In our hospital, mortality among COVID-19 patients with BSI was high. While continued vigilance against these infections is
essential, identification of risk factors for mortality may help to reduce fatal outcomes in patients
with COVID-19.
AB - The aim of this study was to characterize COVID-19 (SARS-CoV-2-infected) patients who
develop bloodstream infection (BSI) and to assess risk factors associated with in-hospital mortality.
We conducted a retrospective observational study of adult patients admitted for 48 h to a large
Central Italy hospital for COVID-19 (1 March to 31 May 2020) who had or had not survived at
discharge. We included only patients having blood cultures drawn or other inclusion criteria satisfied.
Kaplan–Meier survival or Cox regression analyses were performed of 293 COVID-19 patients studied,
46 patients (15.7%) had a hospital-acquired clinically relevant BSI secondary to SARS-CoV-2 infection,
accounting for 58 episodes (49 monomicrobial and 9 polymicrobial) in total. Twelve episodes (20.7%)
occurred at day 3 of hospital admission. Sixty-nine species were isolated, including Staphylococcus
aureus (32.8%), Enterobacterales (20.7%), Enterococcus faecalis (17.2%), Candida (13.8%) and Pseudomonas
aeruginosa (10.3%). Of 69 isolates, 27 (39.1%) were multidrug-resistant organisms. Twelve (54.5%) of 22 patients for whom empirical antimicrobial therapy was inappropriate were infected by a multidrug-resistant organism. Of 46 patients, 26 (56.5%) survived and 20 (43.5%) died. Exploring variables for association with in-hospital mortality identified > 75-year age (HR 2.97, 95% CI 1.15–7.68,p = 0.02), septic shock (HR 6.55, 95% CI 2.36–18.23, p < 0.001) and BSI onset 3 days (HR 4.68, 95% CI 1.40–15.63, p = 0.01) as risk factors independently associated with death. In our hospital, mortality among COVID-19 patients with BSI was high. While continued vigilance against these infections is
essential, identification of risk factors for mortality may help to reduce fatal outcomes in patients
with COVID-19.
KW - COVID-19
KW - COVID-19
UR - http://hdl.handle.net/10807/179182
U2 - 10.3390/jcm10081752
DO - 10.3390/jcm10081752
M3 - Article
SN - 2077-0383
VL - 2021
SP - 1
EP - 12
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
ER -